• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

Zydus Cadila gets USFDA nod to market midodrine hydrochloride tablets

expresspharmaSeptember 04, 2020

Tag: Zydus Cadila , Midodrine Hydrochloride Tablets , FDA

Zydus Cadila received final approval from the USFDA to market Midodrine Hydrochloride Tablets (US RLD- ProAmatine Tablets) in the strengths of 2.5 mg, 5 mg, and 10 mg.

The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 298 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Sanofi, GSK initiate Phase 1/2 clinical trial of COVID-19 vaccine candidate

Next:Dr Reddy’s Labs launch methylphenidate hydrochloride extended-release tablets USP in US

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Zydus Cadila gets USFDA nod to market midodrine hydrochloride tablets | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

You may like
More>>

Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Aciclovir (FDA)

Aciclovir (FDA)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Meclozine HCL (FDA)

Meclozine HCL (FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Adriacin HCL (FDA)

Adriacin HCL (FDA)
GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project
Medroxyprogesterone Acetate(FDA)

Medroxyprogesterone Acetate(FDA)
Fluorfenicol( FDA)

Fluorfenicol( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service